期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

高龄老年房颤患者抗栓治疗的疗效及安全性研究 被引量：14

下载PDF
导出
摘要 目的比较高龄老年心房颤动(房颤)患者不同抗栓方案的疗效及安全性。方法选择该院完成2年随访的住院和门诊房颤患者共157例,根据服用抗栓药物将患者分为3组,即华法林组、阿司匹林组、阿司匹林联合氯吡格雷(双抗)组,观察3组患者心血管血栓事件及出血事件。结果双抗组冠心病和糖尿病患病率高于其他两组(P<0.05),双抗组和华法组脑梗死发生率明显低于阿司匹林组(P<0.05),而双抗组患者在抗栓效果中和华法林组患者无明显区别。在不良事件方面,华法林及双抗组患者的皮肤淤斑明显高于阿司匹林组(P<0.05),双抗组患者皮肤瘀斑的发生率高于华法林组(P<0.05)。结论房颤患者口服华法林或双联抗血小板对抗栓疗效优于阿司匹林,但出血风险明显增加。
作者 罗羽慧 崔坤 尹纯 梅霞
机构地区 重庆市中山医院心内科
出处 《重庆医学》 CAS 北大核心 2015年第22期3107-3109,共3页 Chongqing medicine
基金 重庆市卫生局科研项目(2009-2-114)
关键词 老年人 心房颤动 血栓栓塞 疗效 安全性
分类号 R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献15

  • 1Crandall M, Bradley D, Packer D, et al. Contemporary management of atrial fibrillation: update on anticoagula tion and invasive management strategies [J]. Mayo Clin Proc,2009,84(7) :643-662.
  • 2Spence J. Strokeatrial fibrillation, stroke prevention ther- apy and aging [J]. Nat Rev Cardiol,2009,6(7) :448-450.
  • 3蒋周芩,舒茂琴.心房颤动抗凝治疗及其临床应用进展[J].重庆医学,2013,42(29):3569-3571. 被引量：9
  • 4Marini C,De S,Saeco S,et al. Contribution of atrial fibril- lation to incidence and outcome of ischemic stroke:results from a population based study [J]. Stroke, 2005,36 (6) : 1115-1119.
  • 5Bohm M, Thoenes M, Neuberger H, et al. Atrial fibrilla- tion and heart rate independently correlate to microalbu- minuria in hypertensive patients [J]. Eur Heart J,2009, 30(11) :1364-1371.
  • 6Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Socie- ty of Cardiology (ESC) [J]. Eur Heart J,2010,12(10) : 1360-1420.
  • 7Perez-Gemez F, Iriarte J, Zumalde J, et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial [J]. Eur Heart J, 2007, 28 (8) :996-1003.
  • 8January CT,Wann LS,Aipert JS,et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiolo- gy/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation, 2014,130(23) : e199-267.
  • 9Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrilla- tion:primary results of the prevention of thromboemolic events-European Registry in Atrial Fibrillation (PRE- FER in AF) [J]. Europaee, 2014 ,16 (1) : 6-14.
  • 10Camm AJ,Lip G,De Caterina R,et al. 2012 focused up- date of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the spe- cial contribution of the European Heart Rhythm Associa- tion[J]. Eur Heart J,2012,14(10) :1385-1413.

二级参考文献27

  • 1Go AS, Hylek EM, Borowsky LH, et al. Warfarin use a- mong ambulatory patients with nonvalvular atrial fibrilla- tion:the anticoagulation and risk factors in atrial fibrilla- tion(ATRIA) study[,J]. Ann Intern Med, 1999,131(12) : 927- 934.
  • 2Wan Y, Heneghan C,Perera R,et al. Anticoagulation con- trol and prediction of adverse events in patients with atrial fibrillation : a systematic review[J]. Circ Cardiovasc Qual Outcomes, 2008,1 (2) : 84-91.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: an tithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J]. Ann Intern Med, 2007,146(12) :857-867.
  • 4Goto S,Bhatt DL, Rother J, et al. Prevalence, clinical pro- file,and cardiovascular outcomes of atrial fibrillation pa- tients with atherothrombosis[,J]. Am Heart J, 2008,156 (5) :855-863.
  • 5Camm AJ,Lip GY,De Caterina R,et al. 2012 focused up- date of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the spe- cial contribution of the European Heart Rhythm Associa tion[J]. Europace,2012,14(10) :1385-1413.
  • 6Olesen JB, Fauchier L, Lane DA, et ai. Risk factors for stroke and thromboembolism in relation to age among pa- tients with atrial fibrillation= the Loire Valley Atrial Fi brillation Project[J]. Chest, 2012,141 (1) : 147-153.
  • 7Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk as- sessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the Eu- ropean Heart Rhythm Association [EHRA],endorsed by the European Society of Cardiology IESCJ Working Group on Thrombosis [J]. Thromb Haemost, 2011,106 (6) :997-1011.
  • 8De Caterina R, Husted S,Wallentin L,et al. New oral an- ticoagulants in atrial fibrillation and acute coronary syn- dromes:ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper[J]. J Am Coll Cardiol,2012,59(16) :1413-1425.with warfarin in patients with atrial fibrillation and.
  • 9JW E, JI W. New anticoagulants[J]. Circulation, 2010,121 (13) : 1523-1532.
  • 10Garcia D, Libby E, Ma C. The new oral anticoagulants[J]. Blood,2010,115(1) :15-20.

共引文献119

同被引文献101

  • 1叶显华,袁洪,凌峰,王宁夫,张邢炜.静脉应用地尔硫卓和美托洛尔治疗老年心功能衰竭伴心房颤动快速心室率的疗效和安全性比较[J].中国动脉硬化杂志,2007,15(3):224-226. 被引量：6
  • 2周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量：1397
  • 3张鹤萍,胡大一.非心瓣膜疾病性心房颤动与血栓栓塞[J].中华心血管病杂志,2005,33(10):966-968. 被引量：39
  • 4付文波,丁世芳,杨波.房颤的机制研究现状[J].华南国防医学杂志,2006,20(6):37-40. 被引量：2
  • 5Heeringa J, van der Kuip D A, Hofman A,et al. Preva-lence ,incidence and lifetime risk of atrial fibrillation : theRotterdam study [J]. Eur Heart J,2006,27(8) :949-953.
  • 6Beasley B N, Unger E F,Temple R. Anticoagulant op-tions-why the FDA approved a higher but not a lower dose ofdabigatran? [J].N Engl J Med, 2011,364(19) : 1788-1790.
  • 7European Heart Rhythm Association,European Associationfor Cardio-Thoracic Surgery, Camm A J, et al. Guidelinesfor the management of atrial fibrillation : the task force forthe management of atrial fibrillation of the european societyof cardiology (ESC) [ J]. Europace, 2010,12(10) : 1360-1420.
  • 8European Heart Rhythm Association,European Associationfor Cardio-Thoracic Surgery, Camm A } t et al. Guidelinesfor the management of atrial fibrillation : the task force forthe management of atrial fibrillation of the european society ofcardiology (ESC) [J]. Eur Heart J, 2010,31(19):2369-2429.
  • 9Camm A J,Kirchhof P,Lip G Y t et al. Guidelines for themanagement of atrial fibrillation : the task force for themanagement of atrial fibrillation of the european society ofcardiology (ESC) [ J]. Europace, 2010,12(3) *.1360-1420.
  • 10No authors listed. Risk factors for stroke and efficacy ofantithrombotic therapy in atrial fibrillation. Analysis ofpooled data from five randomized controlled trials [ J ].Arch Intern Med, 1994,154(13) : 1449-1457.

引证文献14

二级引证文献82

重庆医学
2015年 第22期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部